 SEATTLE--BUSINESS WIRE--Omeros Corporation Nasdaq: OMER announced today that the Biologics License Application BLA for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy HSCT-TMA has been accepted for filing by the U.S. Food and Drug Administration FDA. The BLA has been granted Priority Review with an FDA action date of July 17, 2021 under the Prescription Drug User Fee Act PDUFA. FDA also indicated in its filing letter that the 